×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 6: FDA Guidance for Industry on Safety Reporting
Session Chair(s)
Mark Vieder, MBA, RPh
Vice President, Drug Safety and Pharmacovigilance
Biorasi, LLC, United States
This session will review the FDA guidelines on safety reporting that provide recommendations for how sponsors of INDs can identify and evaluate important safety information as well as recommendations for a systematic approach to IND safety reporting.
Have an account?